Physician profile
Mark S Wald
NPI 1194716688
$1,408.08
in general payments reported to CMS, 2019-2025
21 companies · $23.47 in 2025
The $23.47 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $89.89 · 2021: $168 · 2022: $324 · 2023: $320 · 2024: $17.20 · 2025: $23.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.37 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
| Grifols USA, LLC | $182.82 | 2019-2023 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $177.41 | 2019-2023 | Fasenra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $130.05 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $82.05 | 2019-2023 | Dupixent |
| Mylan Specialty L.P. | $64.38 | 2019-2023 | Yupelri |
| Amgen INC. | $62.37 | 2023 | Tezspire |
| United Therapeutics Corporation | $58.80 | 2019-2023 | Tyvaso |
| Genzyme Corporation | $48.36 | 2022 | |
| Jazz Pharmaceuticals INC. | $45.95 | 2019 | |
| Philips North America LLC | $40.36 | 2019 | |
| Mallinckrodt Hospital Products INC. | $39.83 | 2021-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $39.12 | 2019 | |
| Glaxosmithkline, LLC. | $23.87 | 2020-2021 | |
| Noah Medical Corporation | $23.09 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.05 | 2022 | |
| Resmed Corp | $22.19 | 2023 | |
| Genentech USA, INC. | $17.94 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.53 | 2022 | |
| Advanced Respiratory, INC | $15.42 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.